Memory problems are the main symptom of Alzheimer's Disease, but do also occur in many other neuropsychiatric disorders, such as in schizophrenia or depression. Today no satisfactory treatment options for memory impairment are available. The neuroscientists Dominique de Quervain and Andreas Papassotiropoulos of the University of Basel have been working on the characterization of the neurobiological and molecular basis of human memory for several years.
By applying genome-wide studies of large groups of healthy volunteers, they were able to identify important metabolic processes in human memory. The results of those studies provide the researchers with valuable information for the selection of possible targets for potential drugs against memory impairment. Both the molecular genetic studies and clinical trials are being conducted at the Division of Cognitive Neuroscience and the Division of Molecular Neuroscience of the University of Basel.
The Basel researchers use the large-scale information obtained in these studies to develop new medicines for memory impairment. To achieve this goal, the scientists have launched a collaboration with AC Immune. Led by Andrea Pfeifer, the biopharmaceutical company is a leader in Alzheimer´s Disease drug development and will bring its extensive knowledge to the collaboration.
The partner project "Human genetics-driven discovery of memory-modulating drugs" will start in March 2012. Three clinical studies are being supported through a grant of the CTI (Commission of Technology and Innovation) for three years.
For further information please contact:
Prof. Dr. Dominique de Quervain, Director of the Division of Cognitive Neuroscience, University Basel: firstname.lastname@example.org, Phone: +41 61 267 02 37
Prof. Andrea Pfeifer, CEO, AC Immune, Lausanne: email@example.com, Phone: +41 21 693 91 34
Reto Caluori | Universität Basel
Further reports about: > CTI > Cognitive Neuroscience > Cognitive Science > Commission > End User Development > Immune cell activation > Impairment > Mobile phone > Molecular Target > Neuroscience > human memory > information technology > medicines > memory impairment > metabolic process > psychiatric disorder
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy